Tumour-bearing mice were treated with either vehicle, bev (5 mg/kg) or the bi-specific VEGF/Ang2 neutralising compound BI-880 in two different doses (4 mg/kg (BI-8804) or 16 mg/kg (BI-88016)); treatment and schedule is depicted in Fig. 2a. Here, VEGFA is linked to neoplasm.